title: Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin.
abstract: OBJECTIVE
  Adherence to ribavirin is one factor that is critically important in the treatment of hepatitis C virus infection. However, ribavirin can be associated with clinically significant hemolytic anemia resulting in dose modifications in up to one-quarter of patients. Currently, baseline predictors of considerable anemia are not sufficiently discriminating for routine therapeutic intervention. The objective of this analysis was to elucidate baseline and on-treatment factors predictive of a considerable hemoglobin drop at week 4.
  
  
  METHODS
  Multivariate logistic regression analysis was used to explore possible predictors for considerable hemoglobin decline (> or =2.5 g/dL) at week 4 among patients receiving peginterferon alfa-2a (40KD) and ribavirin (1,000/1,200 mg/day).
  
  
  RESULTS
  A total of 555 patients were included in this analysis. At week 4, 236 patients exhibited a > or =2.5 g/dL decrease in hemoglobin. By regression analysis the most important independent variables associated with a decrease in hemoglobin of > or =2.5 g/dL were baseline creatinine clearance (P= 0.0003) and a rapid decline in hemoglobin of > or =1.5 g/dL at week 2 (P < 0.0001). Considerable hemoglobin decreases at week 4 were also significantly associated with early ribavirin dose reductions and a lower cumulative daily dose of ribavirin.
  
  
  CONCLUSIONS
  Patients with impaired renal function may be at an increased risk of ribavirin-related anemia and should be monitored accordingly. Furthermore, a hemoglobin drop of > or =1.5 g/dL by week 2 was an excellent early predictor for subsequent considerable hemoglobin decreases and might be used to identify candidates for early intervention against anemia in order to help maintain ribavirin dosing and avoid suboptimal exposure.
authors.affiliation: Center for Liver Diseases, University of Chicago Hospitals, Chicago, Illinois 60637, USA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Reau
authors.forename: Stephanos J
authors.initials: SJ
authors.lastname: Hadziyannis
authors.forename: Diethelm
authors.initials: D
authors.lastname: Messinger
authors.forename: Michael W
authors.initials: MW
authors.lastname: Fried
authors.forename: Donald M
authors.initials: DM
authors.lastname: Jensen
mesh_terms: D000328:Adult; D000740:Anemia / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000378:metabolism; D006526:Hepatitis C / Q000097:blood* / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D011237:Predictive Value of Tests; D011446:Prospective Studies; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006454:Hemoglobins; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a
references.citation: N Engl J Med. 1998 Nov 19;339(21):1493-9
references.pmid: 9819447
references.citation: J Viral Hepat. 2004 May;11(3):243-50
references.pmid: 15117326
references.citation: Br J Clin Pharmacol. 2006 Dec;62(6):699-709
references.pmid: 17118125
references.citation: Hepatology. 2001 Aug;34(2):395-403
references.pmid: 11481625
references.citation: Hepatology. 2007 Aug;46(2):371-9
references.pmid: 17559152
references.citation: N Engl J Med. 1998 Nov 19;339(21):1485-92
references.pmid: 9819446
references.citation: Ann Intern Med. 2004 Mar 2;140(5):346-55
references.pmid: 14996676
references.citation: Gastroenterology. 2002 Oct;123(4):1061-9
references.pmid: 12360468
references.citation: J Gastroenterol. 2004 Jul;39(7):668-73
references.pmid: 15293138
references.citation: Am J Gastroenterol. 2005 Feb;100(2):299-307
references.pmid: 15667486
references.citation: J Clin Gastroenterol. 2005 Jan;39(1 Suppl):S3-8
references.pmid: 15597025
references.citation: Lancet. 2001 Sep 22;358(9286):958-65
references.pmid: 11583749
references.citation: Clin Infect Dis. 2003;37 Suppl 4:S315-22
references.pmid: 14582000
references.citation: Lancet. 1998 Oct 31;352(9138):1426-32
references.pmid: 9807989
references.citation: Am J Gastroenterol. 2007 Apr;102(4):880-9
references.pmid: 17397412
references.citation: N Engl J Med. 2002 Sep 26;347(13):975-82
references.pmid: 12324553
references.citation: Hepatology. 2007 Oct;46(4):971-81
references.pmid: 17894303